TY - JOUR
T1 - Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
AU - Sen, Abhijit
AU - Papadimitriou, Nikos
AU - Lagiou, Pagona
AU - Perez-Cornago, Aurora
AU - Travis, Ruth C.
AU - Key, Timothy J.
AU - Murphy, Neil
AU - Gunter, Marc
AU - Freisling, Heinz
AU - Tzoulaki, Ioanna
AU - Muller, David C.
AU - Cross, Amanda J.
AU - Lopez, David S.
AU - Bergmann, Manuela
AU - Boeing, Heiner
AU - Bamia, Christina
AU - Kotanidou, Anastasia
AU - Karakatsani, Anna
AU - Tjønneland, Anne
AU - Kyrø, Cecilie
AU - Outzen, Malene
AU - Redondo, María Luisa
AU - Cayssials, Valerie
AU - Chirlaque, Maria Dolores
AU - Barricarte, Aurelio
AU - Sánchez, Maria Jose
AU - Larrañaga, Nerea
AU - Tumino, Rosario
AU - Grioni, Sara
AU - Palli, Domenico
AU - Caini, Saverio
AU - Sacerdote, Carlotta
AU - Bueno-de-Mesquita, Bas
AU - Kühn, Tilman
AU - Kaaks, Rudolf
AU - Nilsson, Lena Maria
AU - Landberg, Rikard
AU - Wallström, Peter
AU - Drake, Isabel
AU - Bech, Bodil Hammer
AU - Overvad, Kim
AU - Aune, Dagfinn
AU - Khaw, Kay Tee
AU - Riboli, Elio
AU - Trichopoulos, Dimitrios
AU - Trichopoulou, Antonia
AU - Tsilidis, Konstantinos K.
N1 - Funding Information:
Key words: coffee, tea, decaffeinated, caffeinated, prostate cancer, EPIC Abbreviations: BMI: body mass index; CI: confidence interval; EPIC: European Prospective Investigation into Cancer and Nutrition; HR: hazard ratio; RR: relative risk; TNM: tumor node-metastasis; WCRF: World Cancer Research Fund Additional Supporting Information may be found in the online version of this article. †Deceased For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http:// epic.iarc.fr/access/index.php Conflict of interest: The authors declare no conflict of interest. Grant sponsor: World Cancer Research Fund; Grant numbers: 2014/1180; Grant sponsor: Medical Research Council; Grant numbers: MR/ M012190/1 (EPIC-Norfolk), 1000143 (EPIC-Oxford); Grant sponsor: Cancer Research UK; Grant numbers: C570/A16491, 14136; Grant sponsor: County Councils of Skåne and Västerbotten (Sweden), Swedish Cancer Society, Swedish Research Council; Grant sponsor: FEDER funds/European Regional Development Fund ERDF; Grant sponsor: ISCIII Health Research Funds; Grant numbers: RD12/0036/0018; Grant sponsor: Regional Governments of Andalucía, Asturias; Grant sponsor: Health Research Fund (FIS); Grant numbers: PI13/01162 (EPIC-Murcia), PI13/00061 (EPIC-Granada); Grant sponsor: Statistics Netherlands (The Netherlands), Dutch ZON (Zorg Onderzoek Nederland), Dutch Prevention Funds; Grant sponsor: LK Research Funds; Grant sponsor: Netherlands Cancer Registry (NKR); Grant sponsor: Dutch Ministry of Public Health, Welfare and Sports (VWS); Grant sponsor: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Grant sponsor: Hellenic Health Foundation (Greece); Grant sponsor: Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); Grant sponsor: Federal Ministry of Education and Research (BMBF), German Cancer Aid, German Cancer Research Center (DKFZ); Grant sponsor: Danish Cancer Society; Grant sponsor: International Agency for Research on Cancer; Grant sponsor: European Commission (DG-SANCO); Grant sponsor: Helse-midt Norge DOI: 10.1002/ijc.31634 History: Received 2 Apr 2018; Accepted 8 May 2018; Online 26 Jun 2018 Correspondence to: Konstantinos K Tsilidis, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK, E-mail: k.tsilidis@imperial.ac.uk; Tel: +44 (0) 2075942623
Publisher Copyright:
© 2018 UICC
PY - 2019/1/15
Y1 - 2019/1/15
N2 - The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
AB - The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
KW - EPIC
KW - caffeinated
KW - coffee
KW - decaffeinated
KW - prostate cancer
KW - tea
UR - http://www.scopus.com/inward/record.url?scp=85056735946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056735946&partnerID=8YFLogxK
U2 - 10.1002/ijc.31634
DO - 10.1002/ijc.31634
M3 - Article
C2 - 29943826
AN - SCOPUS:85056735946
VL - 144
SP - 240
EP - 250
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 2
ER -